Shruti Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.25 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.86 Cr
as on 24-10-2024
- Company Age 30 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 36.17 Cr
as on 24-10-2024
- Revenue 62.62%
(FY 2023)
- Profit 95.39%
(FY 2023)
- Ebitda 267.87%
(FY 2023)
- Net Worth 18.35%
(FY 2023)
- Total Assets 12.27%
(FY 2023)
About Shruti Drugs
The Corporate was formerly known as Shruti Bulk Drugs Pvt Ltd,. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.25 Cr and a paid-up capital of Rs 1.86 Cr.
The company currently has active open charges totaling ₹36.17 Cr.
Nishit Kadakia and Prakash Kadakia serve as directors at the Company.
- CIN/LLPIN
U24230TG1994PTC017903
- Company No.
017903
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shruti Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nishit Kadakia  | Director | 29-Jul-1994 | Current |
| Prakash Kadakia | Director | 24-Jul-1994 | Current |
Financial Performance and Corporate Structure Insights of Shruti Drugs.
Shruti Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 62.62% increase. The company also saw a substantial improvement in profitability, with a 95.39% increase in profit. The company's net worth Soared by an impressive increase of 18.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shruti Drugs?
In 2023, Shruti Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sunsai Laboratories Private LimitedActive 9 years 4 months
Nishit Kadakia and Prakash Kadakia are mutual person
- Redlabs Chemicals Private LimitedActive 8 years 2 months
Nishit Kadakia and Prakash Kadakia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Apr 2024 | ₹6.50 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Jun 2022 | ₹2.00 M | Open |
Others Creation Date: 08 Jul 2020 | ₹14.62 Cr | Open |
How Many Employees Work at Shruti Drugs?
Unlock and access historical data on people associated with Shruti Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shruti Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shruti Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
